Investor Presentation • Jun 7, 2021
Investor Presentation
Open in ViewerOpens in native device viewer
1
LIFE SCIENCE . MASSIVE OPPORTUNITY . MASSIVE IMPACT
This presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any shares or other securities of Merchavia Holdings and Investments Ltd. (the "Company") or any of its affiliated entities nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever. The summary information herein does not purport to be complete. The information in this Presentation should not be relied upon as any representation or warranty, express or implied, of the Company or any of their affiliated entities. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this Presentation.
No legally binding obligations will be created, implied, or inferred from this Presentation.
Everything stated in this Presentation with respect to an analysis of the Company's business is merely a summary and any forward-looking statements involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company. Such forward-looking statements are not guaranteeing of future results, performance or achievements and are based on current expectations, estimations, and assumptions, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this presentation due to a variety of factors, many of which are beyond the Company's control, including, without limitation, certain risk factors contained in the Company's reports. independent third-party sources the accuracy of such information and the assumptions on which such information is based have not been independently verified.
The Company disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations ,estimates, projections and assumptions. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or
LIFE SCIENCE - MASSIVE OPPORTUNITY. MASSIVE IMPACT. \$456 Billion The size of the medical devices market in 2020 reached
\$603 Billion The medical devices market is expected to grow at a CAGR of 6.1% from 2021 and reach
\$84 Billion The global Digital Health Market in 2019 was approximately
\$220 Billion The market is expected to grow at a CAGR of 14.8% and is anticipated to reach around
https://www.globenewswire.com/news-release/2020/10/27/2114984/0/en/Global-Medical-Device-Market-2020-Size-To-Increase-Due-To-Rising-Infectious-And-Chronic-Disease-Cases-As-Per-The-Business-Research-Company-s-Medical-Devices-Global-Market-Opportuni.html Sources:
https://www.globenewswire.com/news-release/2021/03/22/2196996/0/en/Global-Digital-Health-Market-Size-Will-Grow-to-USD-220-94-Billion-by-2026-Facts-Factors.html
3
4
from fewer than 25 cases per 100,000 people in age groups under age 20
to about 350 cases per 100,000 people among those aged 45–49
to more than 1,000 per 100,000 people in age groups 60 years +
Sources: https://www.cancer.gov/about-cancer/causes-prevention/risk/age https://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_449846.pdf
6
Economic burden on global medical systems necessitates change
Early detection of serious and chronic diseases is the key to coping
The solution: Accelerated technological innovation for the medical world
7
Strong management team with a combined background in the fields of capital markets and the life sciences.
Eli Arad
Has vast experience with Israeli startups and served in many leading roles in Israeli biomed companies (Bio-Cell, Biomedix Incubator, D Medical, NasVax, Integra, etc.).
Has extensive experience in all areas of financial management. Previously served for seven years at accounting firm PWC Israel.
Attorney and economist with experience of over 20 years in various senior management positions in the fields of capital markets, finance and energy in Israel and globally.
Dr Schenker has more than 20 years of experience in technological and business development of companies dealing with medical equipment, pharmacology and bio-pharmaceutics.
Dr. Schenker was medical director at Kamada, Neurim, and Neurolief.
Holder of a controlling interest in the company. Certified lawyer (USA) with 40 years of experience managing the Goldstein family's global real-estate investment and 15 years of experience investing in hightech and biotech companies.
Founder and CEO of Cleveland Diagnostics, Inc. Has over 25 years of experience in NASA. Founded and led biomed companies, research companies and companies engaged in optical electronics.
Dr. Arnon Chait USA Director of the Rehabilitation Department at Ichilov Medical Center. Served for 17 years as head of the Rehabilitation Department at the Montefiore Hospital in New York. Initiated several patents in the field of rehabilitation. Has an extensive network of contacts and entrepreneurial vision. Medtech and life sciences consultant to a diverse range of companies, including JUMPSTART, University of Pittsburgh, and more. Formerly served as VP of finance at CardioInsight which was sold to Medtronic in 2015. Weizmann Institute's Yeda Company and of Miles Laboratories (owned by Bayer Germany). Was involved in dozens of
Active in investments for several decades, primarily at the international level. Served as Managing Director of the licensing agreements of developments in the field of life sciences.
CEO of ARROW Israel. Arrow Electronics is a leading global distribution company that supplies electronic components and assemblies to high-tech and electronics companies in Israel and around the world, with a turnover of \$18 billion.
●Detecting
when it can be cured An innovative and proven diagnostic technology platform intended for the diagnosis of cancer in an early stage using blood tests.
MILESTONE The FDA has granted IsoPSA a "Breakthrough Device Designation".
MULTI BILLION DOLLAR MARKET
additional tests for breast cancer, lung cancer and other disease diagnosis
CLINICAL STAGE
ISOPSA first test in the market, FDA submission completed, approval decision estimated in Q1 2022. MERCHAVIA HOLDINGS In January 2021, CDx completed raising \$17 million at a value
Investments to date \$1.5 million
MERCHAVIA HOLDINGS TO DATE 5.5% on Fully Diluted basis
LAST ROUND VALUATION
of \$112 million post money.
EFA develops RevDx. The First Affordable Hand-Held Device for on-thespot CBC tests (Complete Blood Count) with no expertise required.
MILESTONE CBC is the most requested test worldwide and the physician's
"best practice".
Helps diagnose infectious diseases, hematological malignancies and immune system deficiencies.
CLINICAL STAGE Clinical pilot trial with Maccabi.
MERCHAVIA HOLDINGS Investments to date \$0.4 million
MERCHAVIA HOLDINGS TO DATE 7.9% on Fully Diluted basis
LAST ROUND VALUATION \$8.2 M post
Since there is no heating in the process, there is no change in the properties of the cannabis and no production of byproducts that usually occur during heating or burning.
According to marketwatch, the medical cannabis market is expected to grow up to \$39 billion by 2023. Sales of cannabis concentrates to the cannabis market exceeded \$3 billion in 2018.
developed for the pharma industry to the cannabis space.
Device prototype ready, pre-clinical trials completed. Formulation based on synthetic CBD tested for droplet size.
MERCHAVIA HOLDINGS Investments to date \$0.4 million
MERCHAVIA HOLDINGS TO DATE 19.57% on Fully Diluted basis
Cardiacsense have signed distribution agreements for more than \$100M for the next 4 years
Several other near-term applications are in development, including monitoring of other arrhythmias and vital signs such as blood pressure, respiratory rate, and oxygen saturation
The initial focus is on monitoring and detection of atrial fibrillation. CardiacSense received CE clearance for AF detection and expects FDA clearance for AF detection by the end of 2021
MERCHAVIA HOLDINGS Investments to date \$1.4 million
MERCHAVIA HOLDINGS TO DATE 5.57% on Fully Diluted basis
In January 2021 Cardiacsense completed a raise of 2.4 M\$ at a company value of \$70 million pre money
CardiacSense is a dynamic digital health company that has developed best-in class, wearable sensor technology with the sensitivity and specificity required for medical diagnosis and monitoring.
nerve activity.
TrainPain approach is to train the brain to get better - on its own - at regulating According to marketwatch, the chronic pain treatment market is expected to grow to about \$83 billion by 2024.
targeting Fibromyalgia & Neuropathic Pain
TrainPain finalized first clinical trial with High Satisfaction and engagement Among Test Users. Trainpain is in the process of initiating more clinical trials in University of Liege, Mt Sinai Hospital and U. of Haifa.
MERCHAVIA HOLDINGS Investments to date \$0.2 million
MERCHAVIA HOLDINGS TO DATE 5.69% on Fully Diluted basis
Aura detects indoor and outdoor air quality based on real-time monitoring through an array of smart sensors.
"Indoor air is 5 TIMES more polluted than outdoor air" World Health Organization
Marketing and sales, revenues initiated at Q4 2020. 2020 revenues summarized to \$3.8M.
MERCHAVIA HOLDINGS Investments to date \$0.5 million
MERCHAVIA HOLDINGS TO DATE 2.4% on fully diluted basis
management and to become the World's Smartest Air Management Platform, A Data-Driven Air Quality Platform Based on User Behavior Algorithms.
Nervio is developing the world's first AI-DRIVEN neuromonitoring solution. Making neuromonitoring accessible and affordable for any operating room worldwide.
Neuromonitoring is the only tool to prevent nerve injury during surgery. Spine, neck & other surgeries involve high risk of nerve injury. Neuromonitoring is a real-time, complex, error-prone process which is highly dependent on the user's experience and expertise. Nervio is in the process of Developing of an alert system ready for the Clinical validation- and launch clinical studies to prove the efficacy of the alert system.
Less than 20% of all surgeries involved high risk of nerve injury worldwide are monitored, lack of experts and high costs involved limit its worldwide availability
MERCHAVIA HOLDINGS Investments to date 250K NIS
MERCHAVIA HOLDINGS TO DATE 8.6% on Fully Diluted basis
Ocon medical Develops, manufactures, and commercializes innovative women's health products based on its proprietary flexible Nitinol platform, IUB (Intra Uterine Ball).
The first product, Ballerine, is a long term (5 years in current markets) copperbased hormone-free intrauterine contraceptive. It is currently sold in 30 countries. To date, over ~100,000 women have used Ballerine.
The next product based on the same platform is a treatment of abnormal uterine bleeding (AUB) with SEAD (Spherical Endometrial Ablation Device), the product is
in a PHASE IIa clinical trial. Completion of enrolment and results of PHASE IIa clinical trial in The SEAD™. Commencing the enrolment of PHASE IIb clinical trial in The SEAD™. Series A round for executing the regulatory strategy for the Ballerine for FDA approval. Merchavia invested \$350K
MERCHAVIA HOLDINGS TO DATE 7.56% on Fully Diluted basis
Investments with the right timing, after proving technological feasibility
The right team + global strategic connections
Proven successes
Have a question? We'll get back to you promptly.